ENDRA Life Sciences Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2905 USD | -0.21% | -3.81% | -86.30% |
May. 10 | ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024 | CI |
Mar. 28 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.30% | 3.21M | |
+29.51% | 48.16B | |
-1.04% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.15% | 25.59B | |
-22.92% | 18.96B | |
+8.44% | 12.92B | |
+29.18% | 12.03B | |
-1.80% | 11.77B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Auditor Raises 'Going Concern' Doubt